-
Meihua Partners with Getein Biotech to Manufacture COVID-19 Antigen Tests
•
China-based Meihua International Medical Technologies Co., Ltd (NASDAQ: MHUA) has announced a strategic partnership with compatriot firm Getein Biotech Inc. (SHA: 603387) to manufacture and market COVID-19 antigen tests and other in vitro diagnostics (IVD) products. The collaboration aims to enhance the availability and accessibility of diagnostic tools in response…
-
CSPC’s Cleviprex Approved for Clinical Study by China’s NMPA
•
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced receiving approval from the National Medical Products Administration (NMPA) to initiate a clinical study for its pipeline drug candidate cleviprex. The company’s first nanoemulsion, cleviprex, is a dihydropyridine calcium channel blocker being developed to treat hypertension when oral antihypertensive drugs are…
-
Takeda’s Mobocertinib Approved in China for EGFR Exon20ins NSCLC
•
Japan-based Takeda Pharmaceutical Co., Ltd’s (TYO: 4502) China unit has announced receiving marketing approval from the National Medical Products Administration (NMPA) for its lung cancer therapy mobocertinib. The drug is indicated for use in adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have progressed during…
-
MediTrust Health Secures Series C+ Funding with HSBC as Strategic Investor
•
MediTrust Health, the insurance, financing, and direct-to-patient pharmacy subsidiary of China-based Shanghai Pharmaceuticals Holding Co., Ltd, has raised an undisclosed amount in a Series C+ financing round. HSBC joined as a strategic investor, alongside other strategic shareholders including SPH, China Life Reinsurance Co., Ltd, and Shanghai Healthcare Capital (SHC). Focus…
-
Kelun-Biotech’s SKB264 Approved for Phase II Study in EGFR-Mutant NSCLC
•
China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd has announced receiving approval from the National Medical Products Administration (NMPA) to conduct a Phase II clinical study for its drug candidate SKB264. The antibody-drug conjugate (ADC) targets trophoblast cell-surface antigen 2 (TROP2) and will be evaluated in combination with AstraZeneca’s (AZ, NASDAQ: AZN)…
-
BeiGene Outlines Global R&D Strategy at J.P. Morgan Healthcare Summit
•
China-based biotech BeiGene (Nasdaq: BGNE, HKG: 6160) provided an update on its company strategy and R&D plans at this week’s J.P. Morgan Healthcare Summit in San Francisco. BeiGene CEO John Oyler presented the firm’s globally disruptive R&D model, which includes in-house discovery capabilities and new treatment modalities set to drive…
-
Evopoint Biosciences Licenses SOS1 Inhibitor to METiS Therapeutics
•
China-based Evopoint Biosciences has announced a global licensing agreement with US firm METiS Therapeutics Inc., granting METiS exclusive global development and commercialization rights to Evopoint’s SOS1 inhibitor. Under the agreement, METiS Therapeutics will pay Evopoint “hundreds of millions” of US dollars in total upfront payment and milestone payments, along with…
-
Pfizer’s Nurtec ODT Launches in China via Hainan’s Bo’Ao Lecheng Zone
•
US-based Pfizer’s (NYSE: PFE) Nurtec ODT (rimegepant), the world’s first calcitonin gene-related peptide (CGRP) receptor antagonist in rapidly dissolving oral disintegrating tablet form, has become available to patients in China via the Bo’Ao Lecheng Medical Tourism Pilot Zone in Hainan from January 1. The drug is being launched in Hainan…
-
HKEX 2022 Annual Report: IPO Activity Declines Amid Global Challenges
•
The Hong Kong Exchanges and Clearing Ltd (HKEX) has released its annual report for 2022, highlighting a significant downturn in initial public offering (IPO) activity within the city. Overall, the number of new public listings fell by 29.6% year-on-year (YOY) to just 69 IPOs. In terms of capital raised, IPO…
-
Konruns Initiates Phase II Study for KC1036 in Advanced Thymic Tumors
•
Beijing-based Konruns Pharmaceutical Co., Ltd (SHA: 603590) has announced the initiation of a single-arm, open, multi-center Phase II clinical study to assess the efficacy and safety of its Category 1 chemical drug KC1036 in patients with advanced thymoma and thymic carcinoma. The study focuses on patients whose disease has progressed…
-
Dizal’s Sunvozertinib NDA Accepted for Review by China’s NMPA
•
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has announced that its New Drug Application (NDA) filing for sunvozertinib (DZD9008), a next-generation epidermal growth factor receptor (EGFR) inhibitor, has been accepted for review by the National Medical Products Administration (NMPA). The drug is indicated for use in locally advanced or metastatic…
-
HighTide Therapeutics Doses First Patient in Phase IIb Study for HTD1801 in NASH
•
Shenzhen-based HighTide Therapeutics Inc. has announced that the first patient has been dosed in a Phase IIb clinical study for its pipeline candidate HTD1801 in non-alcoholic steatohepatitis (NASH). The randomized, double-blind, placebo-controlled study is designed to assess the histological improvement of HTD1801 compared with placebo in subjects with NASH and…
-
Treadwell Therapeutics’ CFI-402257 Granted Fast-Track Status by FDA
•
China-based clinical-stage biotech Treadwell Therapeutics has announced receiving fast-track status from the US Food and Drug Administration (FDA) for its CFI-402257, a best-in-class inhibitor of threonine tyrosine kinase (TTK, also known as Mps1). The designation was granted for the drug’s potential as a treatment for adult patients with ER+/HER2- advanced…
-
Jiangsu Kanion’s KYS202002A Greenlit for Clinical Study in Multiple Myeloma
•
China-based Jiangsu Kanion Pharmaceutical Co., Ltd (SHA: 600557) has announced receiving approval from the National Medical Products Administration (NMPA) to conduct a clinical study for its pipeline candidate KYS202002A in recurrent/refractory multiple myeloma (R/R MM). This marks a significant step forward in the development of this innovative therapy targeting a…
-
Gaoling Medical Secures Funding for Infrared Thermotherapy Technology
•
Gaoling Medical, a Hangzhou-based developer of systemic infrared thermotherapy technology, has raised an undisclosed amount of money through a strategic financing round led by Huaxia Hengtian. The company’s technology integrates neurobiology, bioenergetics, and medical immunology, focusing on improving core body temperature to address sub-health conditions and various diseases. Therapeutic Applications…
-
Yiling Pharmaceutical’s BIO-008 Accepted for Review by China’s NMPA
•
China-based Yiling Pharmaceutical Co., Ltd (SHE: 002603) has announced that its clinical trial filing for BIO-008, an in-house developed Category 1 biologic being developed to treat advanced solid tumors, has been accepted for review by the National Medical Products Administration (NMPA). This marks a significant step forward in the development…
-
Sino Biopharmaceutical Secures Rights to Biosimilar of Amgen’s Xgeva in China
•
China-based Sino Biopharmaceutical Ltd (HKG: 1177) has announced that its subsidiary CP Pharmaceutical Qingdao has entered into a five-year cooperation agreement with compatriot firm Shandong Boan Biotechnology Co., Ltd. Under the agreement, CP Qingdao has obtained exclusive commercialization rights to LY06006/BA6101, a biosimilar version of US major Amgen’s (NASDAQ: AMGN)…
-
CanSino Biologics to Issue GDRs on SWX Swiss Exchange to Boost Globalization
•
China-based CanSino Biologics (SHA: 688185, HKG: 6185) has announced plans to issue an undisclosed amount of Global Depository Receipts (GDRs) on the SWX Swiss Exchange. The move is part of the company’s strategy to accelerate its globalization efforts, building on multiple emergency use authorizations (EUAs) and conditional approvals for its…
-
Luye Pharma Launches Named Patient Program for Lurbinectedin in Hong Kong
•
China-based Luye Pharma Group (HKG: 2186) has announced the launch of a Named Patient Program (NPP) in Hong Kong, enabling access to lurbinectedin (LY01017), an RNA polymerase II inhibitor used to treat patients with relapsed small-cell lung cancer (SCLC). The program will provide immediate access to the drug for SCLC…
-
Innovent Biologics Doses First Patient in Phase III Study for Mazdutide
•
China-based Innovent Biologics, Inc. (HKG: 1801) has announced that the first patient has been dosed in the multi-center, randomized, double-blind, placebo-controlled Phase III DREAMS-1 study for its mazdutide (IBI362), a glucagon-like peptide-1 (GLP-1) and glucagon receptor dual agonist. The drug is being assessed for safety and efficacy in treating Chinese…
